The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Royan Institute - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Royan Institute human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Royan Institute with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Royan Institute’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Royan Institute’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Royan Institute in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Royan Institute’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Royan Institute.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Royan Institute and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Royan Institute Snapshot 5
Royan Institute Overview 5
Key Information 5
Key Facts 5
Royan Institute - Research and Development Overview 6
Key Therapeutic Areas 6
Royan Institute - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Royan Institute - Pipeline Products Glance 12
Royan Institute - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Royan Institute Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Royan Institute - Drug Profiles 15
Bone marrow derived MNC 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Microdose GnRh agonist 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Autologous Transplantation of Melanocytes 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
BM-MNC + G-CSF 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Bone March row Derived CD 133 Positive Stem Cell + Mono Nuclear Cell (MNC) Transplantation 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Cabergoline + Control 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
CD133 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Human Chorionic Gonadotropin 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Human Chorionic Gonadotropin + Clomiphene Citrate 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Methylprednisolone 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Autologous Bone March row Mesenchymal Stem Cells Transplantation 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
CD133 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Royan Institute - Pipeline Analysis 27
Royan Institute - Pipeline Products by Therapeutic Class 27
Royan Institute Pipeline Products By Target 29
Royan Institute - Pipeline Products by Route of Administration 31
Royan Institute - Pipeline Products by Molecule Type 32
Royan Institute - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 35
Contact Us 35
Disclaimer 35List of Tables
Royan Institute - Pipeline by Therapy Area and Indication, 2010 7
Royan Institute - Pipeline by Stage of Development, 2010 9
Royan Institute - Monotherapy Products in Pipeline, 2010 10
Royan Institute - Combination Treatment Modalities in Pipeline, 2010 11
Royan Institute - Phase III, 2010 12
Royan Institute - Phase II, 2010 13
Royan Institute - Phase I, 2010 14
Royan Institute - Pipeline By Therapeutic Class, 2010 27
Royan Institute - Pipeline By Target, 2010 29
Royan Institute - Pipeline By Route of Administration, 2010 31
Royan Institute - Pipeline By Molecule Type, 2010 32

List of Figures
Royan Institute - Pipeline by Therapy Area and Indication, 2010 7
Royan Institute - Pipeline by Stage of Development, 2010 9
Royan Institute - Monotherapy Products in Pipeline, 2010 10
Royan Institute - Combination Treatment Modalities in Pipeline, 2010 11
Royan Institute - Pipeline By Therapeutic Class, 2010 27
Royan Institute - Pipeline By Target, 2010 29
Royan Institute - Pipeline By Route of Administration, 2010 31
Royan Institute - Pipeline By Molecule Type, 2010 32

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

  • $ 5 000
  • Industry report
  • April 2014
  • by Frost & Sullivan

The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.